MA: Less access for Australians the 'only likely outcome' of US proposal

New Stories

• OncoSil Medical completes recruitment in TRIPP-FFX clinical trial

  July 23, 2025 - - Australian Biotech

• Nyrada advances Xolatryp towards Phase 2a trial in cardioprotection

  July 23, 2025 - - Australian Biotech

• Amplia Therapeutics announces $25 million placement and launches share purchase plan

  July 23, 2025 - - Australian Biotech

• Percheron Therapeutics announces publication of new preclinical HMBD-002 data

  July 23, 2025 - - Australian Biotech

• US leads the way on cell and gene therapy with new rapid access program

  July 23, 2025 - - Latest News

• Neuraxpharm continues international expansion with launch of Australian affiliate

  July 23, 2025 - - Latest News

• Companies secure certification as 'Great Places to Work'

  July 23, 2025 - - Latest News